Capital Advisors Inc. OK Reduces Position in Pfizer Inc. $PFE

Capital Advisors Inc. OK reduced its position in Pfizer Inc. (NYSE:PFE) by 2.9% during the second quarter, HoldingsChannel.com reports. The firm owned 1,770,761 shares of the biopharmaceutical company’s stock after selling 52,013 shares during the period. Capital Advisors Inc. OK’s holdings in Pfizer were worth $42,640,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Evolution Wealth Management Inc. grew its stake in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Keb Asset Management LLC purchased a new position in Pfizer during the 2nd quarter valued at $26,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Field & Main Bank bought a new stake in shares of Pfizer during the second quarter worth $27,000. Institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

Pfizer Stock Down 0.2%

Shares of NYSE PFE opened at $27.95 on Friday. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75. The stock’s fifty day simple moving average is $25.55 and its two-hundred day simple moving average is $26.30. The stock has a market capitalization of $159.31 billion, a PE ratio of 36.78 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the business posted $0.78 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. BMO Capital Markets decreased their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. Guggenheim reduced their target price on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.